- Conditions
- Cancer, Cancer Gene Mutation, PAN Gene Mutation, Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Pan-genomic Testing
- Genetic
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 5,453
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced or Metastatic Solid Tumor, Liver Failure
- Interventions
- Sacituzumab Govitecan-hziy
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 8
- States / cities
- Long Beach, California • Newark, Delaware • Baltimore, Maryland + 3 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pralatrexate, probenecid
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumors
- Interventions
- Wee-1 kinase inhibitor AZD1775
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
- Conditions
- Advanced Solid Tumor
- Interventions
- STP1002
- Drug
- Lead sponsor
- ST Pharm Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Denver, Colorado • Evanston, Illinois
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Malignant Solid Neoplasm, Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis, Idiopathic Cytopenia of Undetermined Significance, Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder, Ovarian Carcinoma, Myeloid Neoplasm Post Cytotoxic Therapy
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
- Interventions
- PQ203
- Drug
- Lead sponsor
- ProteinQure Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Houston, Texas • San Antonio, Texas • West Valley City, Utah
- Conditions
- Advanced Malignant Solid Tumor
- Interventions
- BNT314
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Grand Rapids, Michigan • Huntersville, North Carolina • Cleveland, Ohio
- Conditions
- Advanced Solid Tumors
- Interventions
- AMG 386, Paclitaxel
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Salt Lake City, Utah
- Conditions
- Sarcoma, Solid Tumor
- Interventions
- RAD001, CP-751,871
- Drug
- Lead sponsor
- Suzanne George, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Gastric Adenocarcinoma, Malignant Mesothelioma (MM), Von Hippel Lindau, Bladder Cancer, Bladder Urothelial Carcinoma
- Interventions
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Diagnostic Test
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more
- Conditions
- Central Nervous System (CNS) Metastases, Brain Metastases
- Interventions
- Topotecan, Temozolomide
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, Sotorasib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 180
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Aromatherapy and Essential Oils, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- gemcitabine, soblidotin, chemotherapy
- Drug · Procedure
- Lead sponsor
- Daiichi Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Albuquerque, New Mexico • New York, New York
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Electronic Health Record Review, Three-Dimensional Imaging
- Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Melanoma, Sarcoma
- Interventions
- Biospecimen Collection, Genetic Testing, Medical Chart Review
- Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 12,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2033
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Electronic Health Record Review
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- collagen/aloe vera/vitamin E/lidocaine topical hydrogel
- Dietary Supplement
- Lead sponsor
- Ingalls Memorial Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Harvey, Illinois
- Conditions
- Cancer
- Interventions
- SOR-C13
- Drug
- Lead sponsor
- Soricimed Biopharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer
- Interventions
- R115777 (farnesyl transferase inhibitor), Topotecan
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab
- Drug
- Lead sponsor
- Acepodia Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- San Diego, California • Denver, Colorado • Nashville, Tennessee + 1 more
- Conditions
- Solid Tumors
- Interventions
- LE-DT
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia
- Conditions
- HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer (TNBC)
- Interventions
- NRM-823
- Drug
- Lead sponsor
- Normunity AccelCo, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more